Meeting
2021 ASCO Annual Meeting
PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.
Authors
Fortunato Ciardiello
Second University of Naples, Department of Clinical and Experimental Medicine, Naples, Italy
Fortunato Ciardiello , Yung-Jue Bang , Johanna C. Bendell , Andres Cervantes , Mikhail Dvorkin , Charles D. Lopez , Jean-Philippe Metges , Antonio Sanchez , Mariona Calvo , Andrew Strickland , George Kannourakis , Kei Muro , Hisato Kawakami , Jia Wei , Christophe Borg , Song Mu , Kathy Zhang , Maggie Zhang , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03427814
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3109)
DOI
10.1200/JCO.2021.39.15_suppl.3109
Abstract #
3109
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.
First Author: Fortunato Ciardiello
Poster
2018 ASCO Annual Meeting
A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.
First Author: Fortunato Ciardiello
Poster
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
First Author: Bradley Corr
Poster
2023 ASCO Annual Meeting
A randomized phase II clinical trial of talazoparib maintenance therapy in patients with triple-negative breast cancer who showed platinum-sensitivity on first- or second-line platinum-based chemotherapy: KCSG BR21-10.
First Author: Joohyuk Sohn